Literature DB >> 32959118

Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Joseph Cowling1, Bethany Gorman1, Afrah Riaz1, James R Bundred1,2, Sivesh K Kamarajah1,3, Richard P T Evans1, Pritam Singh4, Ewen A Griffiths5,6.   

Abstract

BACKGROUND: Many patients with gastric cancer present with late stage disease. Palliative gastrectomy remains a contentious intervention aiming to debulk tumour and prevent or treat complications such as gastric outlet obstruction, perforation and bleeding.
METHODS: We conducted a systematic review of the literature for all papers describing palliative resections for gastric cancer and reporting peri-operative or survival outcomes. Data from peri-operative and survival outcomes were meta-analysed using random effects modelling. Survival data from patients undergoing palliative resections, non-resective surgery and palliative chemotherapy were also combined. This study was registered with the PROSPERO database (CRD42019159136).
RESULTS: One hundred and twenty-eight papers which included 58,675 patients contributed data. At 1 year, there was a significantly improved survival in patients who underwent palliative gastrectomy when compared to non-resectional surgery and no treatment. At 2 years following treatment, palliative gastrectomy was associated with significantly improved survival compared to chemotherapy only; however, there was no significant improvement in survival compared to patients who underwent non-resectional surgery after 1 year. Palliative resections were associated with higher rates of overall complications versus non-resectional surgery (OR 2.14; 95% CI, 1.34, 3.46; p < 0.001). However, palliative resections were associated with similar peri-operative mortality rates to non-resectional surgery.
CONCLUSION: Palliative gastrectomy is associated with a small improvement in survival at 1 year when compared to non-resectional surgery and chemotherapy. However, at 2 and 3 years following treatment, survival benefits are less clear. Any survival benefits come at the expense of increased major and overall complications.

Entities:  

Keywords:  Gastrectomy; Stomach neoplasms; Survival

Mesh:

Substances:

Year:  2020        PMID: 32959118      PMCID: PMC7900337          DOI: 10.1007/s12029-020-00519-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  152 in total

1.  Total gastrectomy for gastric cancer: an analysis of postoperative and long-term outcomes through time: results of 413 consecutive cases in a single cancer center.

Authors:  Wilson Luiz da Costa; Felipe J F Coimbra; Héber S C Ribeiro; Alessandro L Diniz; André Luís de Godoy; Igor Correia de Farias; Maria Dirlei F S Begnami; Fernando Augusto Soares
Journal:  Ann Surg Oncol       Date:  2014-10-31       Impact factor: 5.344

2.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

3.  Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis.

Authors:  Sabrina M Ebinger; René Warschkow; Ignazio Tarantino; Bruno M Schmied; Ulrich Güller; Marc Schiesser
Journal:  Gastric Cancer       Date:  2015-09-21       Impact factor: 7.370

4.  Palliative surgery for far-advanced gastric cancer: a retrospective study on 305 consecutive patients.

Authors:  G B Doglietto; F Pacelli; P Caprino; S Alfieri; C Carriero; M Malerba; F Crucitti
Journal:  Am Surg       Date:  1999-04       Impact factor: 0.688

5.  Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?

Authors:  Suhsien Lim; Bart E Muhs; Stuart G Marcus; Elliot Newman; Russel S Berman; Spiros P Hiotis
Journal:  J Surg Oncol       Date:  2007-02-01       Impact factor: 3.454

6.  Lower survival rate for patients with carcinoma of the stomach of Borrmann type IV after gastric resection.

Authors:  Y Maehara; S Moriguchi; H Orita; Y Kakeji; M Haraguchi; D Korenaga; K Sugimachi
Journal:  Surg Gynecol Obstet       Date:  1992-07

7.  Results of combined gastrectomy and pancreatic resection in patients with advanced primary gastric carcinoma.

Authors:  P Piso; T Bellin; H Aselmann; H Bektas; H J Schlitt; J Klempnauer
Journal:  Dig Surg       Date:  2002       Impact factor: 2.588

8.  Is the follow-up of patients operated on for gastric carcinoma of benefit to the patient?

Authors:  M Huguier; S Houry; F Lacaine
Journal:  Hepatogastroenterology       Date:  1992-02

9.  Skeletonizing en-bloc gastrectomy for adenocarcinoma in Caucasian patients.

Authors:  Jean-Marie Collard; Jacques Malaise; Jean-Yves Mabrut; Paul-Jacques Kestens
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

10.  The Value of Palliative Gastrectomy for Gastric Cancer Patients With Intraoperatively Proven Peritoneal Seeding.

Authors:  Kun Yang; Kai Liu; Wei-Han Zhang; Zheng-Hao Lu; Xin-Zu Chen; Xiao-Long Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.